Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma LSE:VRP London Ordinary Share GB00B06GSH43 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 3.225p 3.10p 3.35p 3.225p 3.225p 3.225p 215,435.00 07:43:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -8.9 -0.7 - 82.76

Verona Pharma Share Discussion Threads

Showing 12526 to 12549 of 12550 messages
Chat Pages: 502  501  500  499  498  497  496  495  494  493  492  491  Older
DateSubjectAuthorDiscuss
02/12/2016
07:08
Friday 02 December, 2016 GlaxoSmithKline PLC Relvar Ellipta approved in Japan for COPD RNS Number : 7952Q GlaxoSmithKline PLC 02 December 2016
thebossman
23/11/2016
10:27
I hope the US listing goes somewhat better than it did for Motif Bio (MTFB), which was a disaster as far as the share price was concerned
timbo003
23/11/2016
10:13
Got to think that the US valuation will be a much higher one than a UK centric one -based on its potential. For various reasons many US funds prefer to buy US listed. Currency might be one factor.
meijiman
23/11/2016
09:47
Cracking RNS, onwards and upwards....everything moving into place nicely!
bewise2
23/11/2016
09:42
surely this shows that the team think they have a great product why wold you do this with the costs involved if it was to fail its clinicals ? discuss
oldvic
23/11/2016
09:30
RNS - Looking to float in the US next year.
phowdo
22/11/2016
09:43
Chippenham, UK - 22 November 2016: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading inhaled airways disease focused business, today announces that it has signed a US development and license agreement with Hikma Pharmaceuticals PLC ("Hikma") (through its wholly-owned subsidiary, West-Ward Pharmaceuticals) for Vectura's VR730 product. VR730 is a generic long acting beta-agonist (LABA) for the treatment of Asthma and COPD delivered using Vectura's proprietary dry powder inhalation technology and device. According to IMS, US sales of inhaled DPI and pMDI LABAs were approximately $150 million in 20151.
thebossman
21/11/2016
10:14
>>thanks Vas et al Another thought worth mentioning is that they are unlikely to get an Asthma indication for a product containing vilanterol (only COPD) as FDA really do have it in for LABAs for the treatment of Asthma.
timbo003
21/11/2016
09:47
GSK are filing for a '3-in-1' 'once per day' dry powder cortisone based medicine for those patients who need multiple therapies. 1 Side effects of fluticasone furoate - http://www.rxwiki.com/fluticasone-furoate 2 Side effects of umeclidinium - http://www.incruse.com/risks-and-side-effects.html 3 Side effects of vilanterol - http://www.everydayhealth.com/drugs/fluticasone-vilanterol Such a combination therapy tells me that we really do need a new range of non-cortisone based medicines with a much better side effects profile - thus the potential of RPL554 to become a novel 'first in class' medicine.
vasilis
21/11/2016
07:36
Glaxo have accelerated timing for their triple therapy for COPD in US from 2018 to end 2016.
ewads
21/11/2016
07:35
From the USA.. hTTp://www.investegate.co.uk/glaxosmithkline-plc--gsk-/rns/gsk-files-closed-triple-therapy-for-copd-in-us/201611210702416611P/
thebossman
28/10/2016
07:21
This news from the NA Cystic Fibrosis Conference in Orlando has been on the Radio 4 Today programme this morning - http://www.bbc.co.uk/news/health-37795460 Note that due to very high costs (£100,000 per patient per annum) it is not available on the NHS, and it only seems to be effective for around half CF patients. So it's worth pointing out again the relevant paragraph from Verona's RNS on Monday in relation to today's news from Orlando - 'In clinical trials, RPL554 has been observed to be an effective bronchodilator and to have anti-inflammatory properties in vitro as well as in a standard inhaled lipopolysaccharide challenge study in healthy volunteers. In these studies, the drug candidate has been well tolerated. Pre-clinical data to date has suggested that RPL554 is also a stimulator of the CFTR, which is dysfunctional in cells of cystic fibrosis patients. Based on these observed favorable properties, the Company believes RPL554 may improve mucociliary clearance (reduce phlegm in the airways), reduce symptoms of chronic inflammation and ease breathing.' Bearing in mind that RPL554 may also be a stimulator of the CFTR in similar fashion to lumicaftor/vacaftor, and the NHS's current position with regards to very high costs per treatment per patient per annum, if Verona can show further positive data then surely they will be knocking on an open door to get orphan drug status for CF - especially with the current backing of the CF Trust. We also still await to hear if anything 'new' has been announced in Orlando as per Monday's RNS.
vasilis
26/10/2016
11:08
...spoke too soon!!
haff1
26/10/2016
08:42
...and an encouraging bounce off the 3.75p line too..
haff1
26/10/2016
07:17
Agreed Tim. No doubt the award was made on the basis of new positive data. I would very much like to see the details of that data to be made available over the next few days - 'New pre-clinical data of RPL554 in CF will be available from 26 October 2016 and presented during two poster sessions on 27 and 28 October 2016 at the Annual North American Cystic Fibrosis Conference in Orlando, Florida.'
vasilis
22/10/2016
06:27
New CF trial: hTTps://clinicaltrials.gov/ct2/show/study/NCT02919995?term=rpl554&rank=3
bewise2
21/10/2016
15:43
When is the Nasdaq quoting taking place?tia
bobic
21/10/2016
14:16
Well one thing is certain and that's that US fund managers would give a much higher valuation to this and may be happier to buy a NASDAQ quoted vehicle.
meijiman
21/10/2016
14:07
Well, what's going on all of a sudden...?
huntie2
19/10/2016
14:01
I think you may be right. I understand that the proposed NASDAQ listing will be some sort of Depository Interest like an ADR or ADS so the Xetra listing may no longer be needed as it would an extra layer of complexity when creating or splitting the ADRs or ADSs. More sensible to have one listing of the GBP shares on the LSE and one for the US ADRs or ADSs only.
tomgreg
19/10/2016
12:45
Maybe they have decided it's not worth having 3 different listings in future, so they are cleaning up before announcing a new listing on Nasdaq.
drradcliffe
19/10/2016
12:28
http://www.investegate.co.uk/verona-pharma-plc--vrp-/prn/notice-of-cancellation-of-trading-on-xetra/20161019130000P40DB/
aimshares
19/10/2016
12:27
You are making the assumption that the share price rise is linked to the RNS. It might well be. Perhaps cost savings? Clearly the company has decided that that listing had no tangible benefits. Any other views???
meijiman
19/10/2016
12:16
...not sure why this move is being seen as so positive?
haff1
Chat Pages: 502  501  500  499  498  497  496  495  494  493  492  491  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20161208 00:13:25